Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer

Journal of the National Cancer Institute
Na LiIan G Campbell

Abstract

Loss-of-function variants in RAD51C are associated with familial ovarian cancer, but its role in hereditary breast cancer remains unclear. The aim of this study was to couple breast tumor sequencing with case-control data to clarify the contribution of RAD51C to hereditary breast cancer. RAD51C was sequenced in 3080 breast cancer index cases that were negative in BRCA1/2 clinical tests and 4840 population-matched cancer-free controls. Pedigree and pathology data were analyzed. Nine breast cancers and one ovarian cancer from RAD51C variant carriers were sequenced to identify biallelic inactivation of RAD51C, copy number variation, mutational signatures, and the spectrum of somatic mutations in breast cancer driver genes. The promoter of RAD51C was analyzed for DNA methylation. A statistically significant excess of loss-of-function variants was identified in 3080 cases (0.4%) compared with 2 among 4840 controls (0.04%; odds ratio = 8.67, 95% confidence interval = 1.89 to 80.52, P< .001), with more than half of the carriers having no personal or family history of ovarian cancer. In addition, the association was highly statistically significant among cases with estrogen-negative (P <. 001) or triple-negative cancer (P < .001), but ...Continue Reading

References

Aug 16, 2008·Breast Cancer Research and Treatment·Simon A JoossePetra M Nederlof
Jul 11, 2009·Breast Cancer Research : BCR·Olafur Andri StefanssonJorunn Erla Eyfjord
Apr 20, 2010·Nature Genetics·Fiona VazChristopher G Mathew
May 28, 2011·Human Molecular Genetics·Liisa M PelttariHeli Nevanlinna
Apr 28, 2012·Nature Genetics·Chey LovedayNazneen Rahman
May 12, 2012·Cancer Discovery·Nicolai J BirkbakAndrea L Richardson
Mar 21, 2013·Molecular Cancer Therapeutics·Ahrum MinYung-Jue Bang
Aug 6, 2014·Breast Cancer Research : BCR·Johnathan A WatkinsAndrew N J Tutt
Aug 30, 2014·Molecular Oncology·Hans Kristian Moen VollanCarlos Caldas
Dec 7, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Philip C SchoutenSabine C Linn
Aug 12, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Honglin SongPaul D P Pharoah
Jan 21, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ella R ThompsonIan G Campbell
Mar 10, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Melinda L TelliAndrea L Richardson
May 12, 2017·Therapeutic Advances in Medical Oncology·Tarra Evans, Ursula Matulonis
Feb 8, 2018·European Journal of Medical Genetics·Ana Isabel Sánchez-BermúdezFrancisco Ruiz-Espejo
Feb 13, 2018·The Journal of Pathology·Jue Er Amanda LeeIan G Campbell
Mar 6, 2018·Journal of the National Cancer Institute·Britta WeigeltGeorgia Chenevix-Trench
Apr 3, 2018·Drug Design, Development and Therapy·Ilaria ColomboAmit Manulal Oza
Aug 14, 2018·Journal of the National Cancer Institute·Hermela ShimelisFergus J Couch

❮ Previous
Next ❯

Citations

Feb 29, 2020·Journal of the National Cancer Institute·Xin YangAntonis C Antoniou
Feb 6, 2020·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hee-Chul ShinWonshik Han
Aug 19, 2020·Breast Cancer Research and Treatment·Maryam BagherzadehMohammad R Akbari
Aug 26, 2019·Breast Cancer Research and Treatment·Roxana CerretiniMohammad R Akbari
Apr 7, 2021·Journal of the National Cancer Institute·Ke-Da YuUNKNOWN SPECTRUM Investigators
Jul 11, 2021·Nucleic Acids Research·Jihae ShinBin Tian
Aug 24, 2021·Current Treatment Options in Oncology·Anusha Vaidyanathan, Virginia Kaklamani
Dec 20, 2021·Human Mutation·Jacopo BoniBarbara Rivera

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.